Company Filing History:
Years Active: 2024-2025
Title: Ji Liu - Innovator in KRAS Degrader Compounds
Introduction
Ji Liu is a prominent inventor based in Bellevue, WA (US). He has made significant contributions to the field of biotherapeutics, particularly in the development of novel compounds targeting KRAS mutations. With a total of 2 patents, his work is paving the way for advancements in cancer treatment.
Latest Patents
Ji Liu's latest patents include innovative glutarimide-containing pan-KRAS-mutant degrader compounds. These compounds exhibit KRAS degradation activities and are formulated into pharmaceutical compositions. The applications of these compounds are focused on the prevention and treatment of various diseases and conditions associated with KRAS mutations.
Career Highlights
Ji Liu is currently associated with Tiger Biotherapeutics Inc., where he continues to push the boundaries of research in biotherapeutics. His expertise in developing targeted therapies has positioned him as a key player in the industry.
Collaborations
Throughout his career, Ji Liu has collaborated with notable colleagues, including Robert Luo and Pin Huang. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Ji Liu's contributions to the field of biotherapeutics, particularly through his patents on KRAS degrader compounds, highlight his role as an influential inventor. His work is instrumental in advancing treatment options for patients with KRAS-related conditions.